Stockscreener 앱 받기
3.26
1.24%
0.04
시간 외 거래:
3.26
전일 마감가:
$3.22
열려 있는:
$3.31
하루 거래량:
63,480
Relative Volume:
0.46
시가총액:
$1.16B
수익:
$890.87M
순이익/손실:
$-115.85M
주가수익비율:
-9.9969
EPS:
-0.3261
순현금흐름:
$-104.29M
1주 성능:
+23.95%
1개월 성능:
+31.98%
6개월 성능:
-15.98%
1년 성능:
-9.44%
1일 변동 폭
$3.24
$3.355
1주일 범위
$2.69
$3.355
52주 변동 폭
$2.308
$4.80
Evotec Se Adr Stock (EVO) Company Profile
Compare EVO vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
3.26 | 1.16B | 890.87M | -115.85M | -104.29M | -0.3261 |
TAK
Takeda Pharmaceutical Co Adr
|
17.82 | 56.30B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
122.38 | 51.46B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.75 | 43.42B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.40 | 37.73B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
588.38 | 25.79B | 3.18B | 1.33B | 1.04B | 27.90 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-15 | 재개 | H.C. Wainwright | Buy |
| 2026-02-03 | 개시 | Berenberg | Buy |
| 2025-04-24 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-10-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-08-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-07-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-07-11 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-04-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-01-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-06-23 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-06-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-06-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-04-04 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-12-09 | 개시 | H.C. Wainwright | Buy |
| 2022-11-16 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2022-08-10 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2022-03-02 | 재개 | Cowen | Outperform |
| 2022-01-07 | 재개 | Citigroup | Neutral |
모두보기
Evotec Se Adr 주식(EVO)의 최신 뉴스
Evotec SE stock (DE0005664809): Is its drug discovery platform strong enough for biotech recovery? - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery pipeline strong enough to unlock biotech upsid - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery platform strong enough to unlock biotech upsid - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery partnership model strong enough for steady ups - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery partnership model strong enough for biotech re - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery model strong enough to unlock biotech upside? - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery model strong enough to unlock new upside? - AD HOC NEWS
Evotec Q4 2025 slides: strong finish masks segment headwinds By Investing.com - Investing.com Australia
BofA reiterates Evotec stock Underperform rating on execution concerns - Investing.com
Evotec (NASDAQ: EVO) pivots to asset-light model and boosts 2025 liquidity - Stock Titan
Evotec Q4 2025 slides: strong finish masks segment headwinds - Investing.com
Earnings call transcript: Evotec SE ADR Q4 2025 sees revenue growth, stock surges - Investing.com
Evotec sees weak 2026 outlook after in-line 2025 results, $100 mln deal By Investing.com - Investing.com South Africa
Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal - Benzinga
Evotec's B2B Partner Search Initiative: Unlocking Strategic Collaborations in Drug Discovery for Nor - AD HOC NEWS
Evotec SE to Announce Fourth Quarter and Full-Year 2025 Results on April 8, 2026 - ChartMill
Evotec appoints Ashiq Khan as chief commercial officer - Investing.com
Evotec Appoints Dr. Ashiq H. Khan as Chief Commercial Officer - ChartMill
Evotec SE Stock: Drug Discovery Leader Faces Restructuring Challenges Ahead of Key Earnings - AD HOC NEWS
Evotec SE stock faces pressure amid biotech sector volatility and partnership updates - AD HOC NEWS
Evotec SE Stock Faces Pressure Amid Biotech Sector Headwinds and Pipeline Updates in Q1 2026 - AD HOC NEWS
JustEvotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses - ChartMill
FreightCar America Posts Downbeat Q4 Results, Joins BioNTech, PROG Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Evotec Aktie | DE0005664809 | ETR:EVT | News & Aktienkurs | FRA:EVT - LYNX Online Broker
Evotec shares surge 8% as Berenberg initiates with “buy” on partner value By Investing.com - Investing.com South Africa
Is Evotec SE (EVO) One of the Best Debt-Free Penny Stocks to Buy Right Now? - Finviz
Financial Review: Evotec (NASDAQ:EVO) & Savara (NASDAQ:SVRA) - Defense World
Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations - Chartmill
Taxes of Evotec SE Sponsored ADR – LSX:A0QZ3J - TradingView — Track All Markets
EvotecHow Low A Company May Go While Still Being Attractive (NASDAQ:EVO) - Seeking Alpha
Evotec AG Earnings Call: Resilience Amidst Challenges - MSN
Evotec AG Reports Strategic Shift Amid Mixed Performance - MSN
Annual General Meeting - Evotec
Investor Relations - Evotec
Evotec shares tumble 9% as drug discovery segment weakens - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Should I buy Evotec (EVO) - zacks.com
Stock Information - Evotec
Evotec SE ADR earnings missed by $0.07, revenue fell short of estimates - Investing.com Australia
Evotec AG Reports Mixed H1 2025 Performance - TipRanks
Evotec Se Adr (EVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.84%
6.22%
자본화:
|
볼륨(24시간):